|
|
Article: Boston Biomedica Presents Pathogen Inactivation Data Using Pressure Cycling Technology (PCT) at Blood Safety Conference.
- Article from:
- PR Newswire
- Article date:
- February 26, 1999
CopyrightCOPYRIGHT 1999 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
WEST BRIDGEWATER, Mass., Feb. 26 /PRNewswire/ -- Boston Biomedica, Inc. (Nasdaq: BBII) announced today that early results on its proprietary Pressure Cycling Technology (PCT) show the ability of the PCT process to inactivate pathogens in plasma while preserving the therapeutic properties of important plasma proteins. In data presented at Cambridge Healthtech Institute's Fifth Annual Blood Safety and Screening Conference in McLean, VA, Mark Manak, Ph.D., Sr. Vice President for Research and Development at BBI, illustrated PCT's effectiveness in killing certain bacteria, yeast and viruses, while the activity of coagulation factors, antibodies, enzymes and growth factors was ...